RMD vs WST — Key Metrics
| Metric | RMD (RESMED INC) | WST (WEST PHARMACEUTICAL SERVICES INC) |
|---|---|---|
| Price | 242.61 | 404.02 |
| Market Cap | 34.12 Billion | 28.14 Billion |
| P/E (TTM) | 22.04 | 45.04 |
| P/B (Quarterly) | 5.438 | 9.779 |
| P/S (TTM) | 5.95 | 8.29 |
| Net Profit Margin (TTM) | 27.8 | 18.8 |
| Gross Margin (TTM) | 61.1 | 37.6 |
| ROE (TTM) | 25.1 | 21.1 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Outperform
Greatly Underperform
Recommendation Summary
Stock RMD is projected to outperform the market, stock WST is projected to greatly underperform the market. Upfront Recommendation: RMD.
Financial Metrics
| RMD | Metrics | WST |
|---|---|---|
| $242.61 | Price | $404.02 |
| — | Market Capitalization | — |
| 22.04 | Price to Earnings Ratio | 45.04 |
| 5.95 | Price to Sales | 8.29 |
| 21.21 | Price to FCF Ratio | 48.5 |
| 9.75 | Price to Gross Profit | 22.04 |
| 86.65 | Price to R&D | 372.28 |
| 9.73 | Price to Current Assets | 15.49 |
RMD vs WST at a glance
Resmed INC (RMD) and West Pharmaceutical Services INC (WST) are both Medical Instruments & Supplies companies in the Healthcare sector. RMD is the larger, at $34.1 billion in market value against $28.1 billion for WST, about 1.2 times the size.
On trailing-twelve-month figures, RMD trades at 22.0 times trailing earnings and WST at 45.0; net profit margins are 27.8% and 18.8%.
The Upfront Investment model currently rates RMD Outperform and WST Greatly Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.